	US 11,938,218 B2
	High density peptide polymers
Angela P. Blum, San Diego, CA (US); Jacquelin K. Kammeyer, San Diego, CA (US); and Nathan C. Gianneschi, San Diego, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Jan. 28, 2021, as Appl. No. 17/160,588.
Application 17/160,588 is a continuation of application No. 15/502,166, granted, now 10,980,744, previously published as PCT/US2015/044515, filed on Aug. 10, 2015.
Claims priority of provisional application 62/035,313, filed on Aug. 8, 2014.
Prior Publication US 2021/0283054 A1, Sep. 16, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/107 (2006.01); A61K 9/14 (2006.01); A61K 47/42 (2017.01); A61K 47/58 (2017.01); C07K 14/00 (2006.01); C08G 61/08 (2006.01)

CPC A61K 9/1075 (2013.01) [A61K 9/146 (2013.01); A61K 47/42 (2013.01); A61K 47/58 (2017.08); C07K 14/001 (2013.01); C08G 61/08 (2013.01); C08G 2261/126 (2013.01); C08G 2261/1424 (2013.01); C08G 2261/1432 (2013.01); C08G 2261/148 (2013.01); C08G 2261/164 (2013.01); C08G 2261/1644 (2013.01); C08G 2261/1646 (2013.01); C08G 2261/3324 (2013.01); C08G 2261/334 (2013.01); C08G 2261/418 (2013.01); C08G 2261/80 (2013.01); C08G 2261/90 (2013.01); C08G 2261/94 (2013.01)]

28 Claims

1. A copolymer having the formula:

R¹-[M(O)]_n-[M(P)]_m—R²

wherein,

n and m are each an integer from 2 to 1000, provided that n is greater than m;

M is a polymerized ROMP polymerizable monomer;

O is independently a therapeutic polypeptide covalently attached to M through a covalent linker; wherein the therapeutic polypeptide is capable of treating a disease and is a cell growth or proliferation inhibitory peptide, an anti-inflammatory peptide, an anti-tumor or anti-cancer peptide, an anti-apoptotic peptide, anti-diabetic peptide, anti-obesity peptide, anti-infective peptide, anti-bacterial peptide, anti-viral peptide, a peptide for promoting cell growth and differentiation, a peptide for treating pain, a peptide for treating neural degeneration or peptides for promoting neurogenesis;

P is independently a non-polypeptide moiety; and

R¹and R²are independently terminal polymer moieties,

wherein the polymerizable monomer is N-substituted-5-norbornene-2,3-dicarboximide,

wherein the substitution comprises the therapeutic polypeptide, and

wherein the therapeutic polypeptide comprises from 5 to 2000 amino acids.